Fecal transplants, which are used to treat recurrent Clostridium difficile infection, could also benefit patients with other gastrointestinal diseases, such as constipation, irritable bowel syndrome and inflammatory bowel disease, according to a report from researchers at Montefiore Medical Center in New York. Researchers said long-term follow-up of one study showed C. diff patients had a 91% primary and 98% secondary cure rate with fecal microbiota transplantation.

Full Story:
Vaccine News Daily

Related Summaries